1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Hemmi, H.
Yoshida, T.
Kumazaki, T.
Nemoto, N.
Hasegawa, J.
Nishioka, F.
Kyogoku, Y.
Yokosawa, H.
Kobayashi, Y.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Biochemistry
BICHAW
0033
0006-2960
41
10657
10664
10.1021/bi026035o
12186551
Solution structure of ascidian trypsin inhibitor determined by nuclear magnetic resonance spectroscopy.
2002
10.2210/pdb1iw4/pdb
pdb_00001iw4
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1
SINGLE WAVELENGTH
M
1
1.0
6084.985
trypsin inhibitor
1
nat
polymer
no
no
AHMDCTEFNPLCRCNKMLGDLICAVIGDAKEEHRNMCALCCEHPGGFEYSNGPCE
AHMDCTEFNPLCRCNKMLGDLICAVIGDAKEEHRNMCALCCEHPGGFEYSNGPCE
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
Halocynthia
sample
7729
Halocynthia roretzi
database_2
pdbx_database_status
pdbx_nmr_software
pdbx_nmr_spectrometer
pdbx_struct_assembly
pdbx_struct_oper_list
database_2
pdbx_database_status
repository
Initial release
Version format compliance
Version format compliance
Data collection
Database references
Derived calculations
Other
Database references
Other
1
0
2002-08-28
1
1
2008-04-27
1
2
2011-07-13
1
3
2020-02-26
1
4
2023-06-14
_pdbx_database_status.status_code_cs
_pdbx_nmr_software.name
_pdbx_nmr_spectrometer.model
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.status_code_nmr_data
5348 is chemical shifts of this protein
PDBJ
Y
PDBJ
2002-04-19
REL
REL
REL
REL
The structure was determined using standard 2D homonuclear techniques.
structures with the lowest energy
100
20
NOESY
DQF-COSY
E-COSY
TOCSY
TOCSY
3.7
ambient
303
K
3.7
ambient
303
K
simulated annealing
1
lowest energy
1.5-2.0mM ascidian trypsin inhibitor; 90% H2O, 10% D2O
90% H2O/10% D2O
1.5-2.0mM ascidian trypsin inhibitor; D2O
D2O
Bruker
collection
XwinNMR
2.6
Delaglio
processing
NMRPipe
2.1
Garrett
data analysis
NMRPIPP
4.3.2
Brunger
refinement
CNS
1.0
500
Bruker
AVANCE
600
Bruker
DRX
750
Bruker
DMX
600
JEOL
A
ALA
1
n
1
ALA
1
A
HIS
2
n
2
HIS
2
A
MET
3
n
3
MET
3
A
ASP
4
n
4
ASP
4
A
CYS
5
n
5
CYS
5
A
THR
6
n
6
THR
6
A
GLU
7
n
7
GLU
7
A
PHE
8
n
8
PHE
8
A
ASN
9
n
9
ASN
9
A
PRO
10
n
10
PRO
10
A
LEU
11
n
11
LEU
11
A
CYS
12
n
12
CYS
12
A
ARG
13
n
13
ARG
13
A
CYS
14
n
14
CYS
14
A
ASN
15
n
15
ASN
15
A
LYS
16
n
16
LYS
16
A
MET
17
n
17
MET
17
A
LEU
18
n
18
LEU
18
A
GLY
19
n
19
GLY
19
A
ASP
20
n
20
ASP
20
A
LEU
21
n
21
LEU
21
A
ILE
22
n
22
ILE
22
A
CYS
23
n
23
CYS
23
A
ALA
24
n
24
ALA
24
A
VAL
25
n
25
VAL
25
A
ILE
26
n
26
ILE
26
A
GLY
27
n
27
GLY
27
A
ASP
28
n
28
ASP
28
A
ALA
29
n
29
ALA
29
A
LYS
30
n
30
LYS
30
A
GLU
31
n
31
GLU
31
A
GLU
32
n
32
GLU
32
A
HIS
33
n
33
HIS
33
A
ARG
34
n
34
ARG
34
A
ASN
35
n
35
ASN
35
A
MET
36
n
36
MET
36
A
CYS
37
n
37
CYS
37
A
ALA
38
n
38
ALA
38
A
LEU
39
n
39
LEU
39
A
CYS
40
n
40
CYS
40
A
CYS
41
n
41
CYS
41
A
GLU
42
n
42
GLU
42
A
HIS
43
n
43
HIS
43
A
PRO
44
n
44
PRO
44
A
GLY
45
n
45
GLY
45
A
GLY
46
n
46
GLY
46
A
PHE
47
n
47
PHE
47
A
GLU
48
n
48
GLU
48
A
TYR
49
n
49
TYR
49
A
SER
50
n
50
SER
50
A
ASN
51
n
51
ASN
51
A
GLY
52
n
52
GLY
52
A
PRO
53
n
53
PRO
53
A
CYS
54
n
54
CYS
54
A
GLU
55
n
55
GLU
55
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
identity operation
0.0000000000
0.0000000000
0.0000000000
A
O
GLU
31
A
O
GLU
31
A
N
ALA
24
A
N
ALA
24
A
N
VAL
25
A
N
VAL
25
A
O
GLU
48
A
O
GLU
48
1
A
A
O
N
ASN
MET
15
17
2.00
1
A
A
O
N
LEU
ARG
11
13
2.01
2
A
A
O
N
ASN
MET
15
17
2.03
2
A
A
O
N
LEU
ARG
11
13
2.11
3
A
A
O
N
ASN
MET
15
17
2.01
3
A
A
O
N
LEU
ARG
11
13
2.11
4
A
A
O
H
LEU
ARG
11
13
1.49
4
A
A
O
N
LEU
ARG
11
13
2.03
5
A
A
O
H
ASN
MET
15
17
1.28
5
A
A
O
N
ASN
MET
15
17
2.15
5
A
A
O
N
LEU
ARG
11
13
2.18
6
A
A
O
H
LEU
GLY
21
52
1.46
6
A
A
O
H
LYS
LEU
16
18
1.48
6
A
A
O
N
ASN
MET
15
17
2.05
6
A
A
O
N
LEU
ARG
11
13
2.06
7
A
A
O
N
ASN
MET
15
17
2.02
7
A
A
O
N
LEU
ARG
11
13
2.03
8
A
A
O
H
LYS
LEU
16
18
1.58
8
A
A
O
N
ASN
MET
15
17
2.03
8
A
A
O
N
LEU
ARG
11
13
2.05
9
A
A
O
H
LYS
LEU
16
18
1.50
9
A
A
O
N
ASN
MET
15
17
2.05
9
A
A
O
N
LEU
ARG
11
13
2.14
10
A
A
O
N
ASN
MET
15
17
2.03
11
A
A
O
N
LEU
ARG
11
13
2.17
12
A
A
O
H
ASN
MET
15
17
1.34
12
A
A
O
N
LEU
ARG
11
13
2.07
13
A
A
O
N
ASN
MET
15
17
2.03
13
A
A
O
N
LEU
ARG
11
13
2.13
14
A
A
O
N
LEU
ARG
11
13
2.11
15
A
A
O
H
ASN
MET
15
17
1.42
15
A
A
O
N
ASN
MET
15
17
2.04
15
A
A
O
N
LEU
ARG
11
13
2.13
16
A
A
O
N
ASN
MET
15
17
2.03
16
A
A
O
N
LEU
ARG
11
13
2.05
17
A
A
O
N
LEU
ARG
11
13
2.01
18
A
A
O
N
ASN
MET
15
17
2.04
19
A
A
O
N
ASN
MET
15
17
2.03
19
A
A
O
N
LEU
ARG
11
13
2.03
20
A
A
O
H
LYS
LEU
16
18
1.53
20
A
A
O
N
ASN
MET
15
17
2.04
20
A
A
O
N
LEU
ARG
11
13
2.17
20
A
A
O
N
LYS
LEU
16
18
2.19
1
A
HIS
2
-69.58
84.64
1
A
GLU
7
-42.07
78.05
1
A
PHE
8
-160.68
-147.67
1
A
ASN
9
-69.11
-71.28
1
A
LEU
11
-47.84
171.42
1
A
CYS
12
-28.00
62.98
1
A
ARG
13
-92.38
41.48
1
A
LYS
16
-20.44
57.49
1
A
MET
17
-65.09
78.58
1
A
LEU
18
-170.87
59.39
1
A
ASP
20
-54.43
178.25
1
A
LEU
21
-170.35
66.11
1
A
ASP
28
-154.08
24.22
2
A
HIS
2
-114.91
52.39
2
A
THR
6
-61.16
-116.85
2
A
GLU
7
179.37
26.38
2
A
PRO
10
-67.06
87.58
2
A
LEU
11
-47.81
-167.97
2
A
CYS
12
-17.79
60.71
2
A
ARG
13
-98.22
42.85
2
A
LYS
16
-19.45
58.21
2
A
LEU
18
-162.65
59.18
2
A
ASP
28
-152.47
23.59
2
A
PHE
47
-61.92
-122.87
2
A
CYS
54
-164.16
-73.03
3
A
HIS
2
-69.83
72.48
3
A
MET
3
-170.87
103.49
3
A
ASP
4
179.54
30.79
3
A
THR
6
-62.14
-124.33
3
A
GLU
7
179.13
24.56
3
A
PRO
10
-66.92
71.85
3
A
LEU
11
-54.78
-170.62
3
A
CYS
12
-17.97
65.85
3
A
ARG
13
-80.37
30.69
3
A
ASN
15
-160.71
-53.40
3
A
LYS
16
-19.71
57.75
3
A
LEU
18
-171.18
63.25
3
A
ASP
28
-154.91
24.28
3
A
PHE
47
-48.82
167.21
3
A
CYS
54
177.06
-36.66
4
A
MET
3
-171.85
-62.46
4
A
ASP
4
-23.70
118.10
4
A
CYS
5
-160.67
-159.70
4
A
GLU
7
-34.63
89.81
4
A
PHE
8
-160.02
-155.80
4
A
LEU
11
-57.03
179.59
4
A
CYS
12
-37.18
63.18
4
A
ARG
13
-91.88
41.53
4
A
ASN
15
-104.09
-73.45
4
A
MET
17
-19.75
142.15
4
A
LEU
18
-68.82
69.35
4
A
ASP
28
-150.82
22.38
4
A
PHE
47
-52.73
-125.83
4
A
CYS
54
-168.61
-59.28
5
A
ASP
4
179.90
76.63
5
A
THR
6
-52.88
-105.11
5
A
GLU
7
178.29
-22.31
5
A
PRO
10
-67.77
70.92
5
A
LEU
11
-51.21
-160.24
5
A
CYS
12
-16.03
69.58
5
A
ARG
13
-97.06
31.58
5
A
LYS
16
-51.40
55.76
5
A
MET
17
-44.42
89.48
5
A
LEU
18
-170.43
52.29
5
A
ASP
20
-69.79
-179.53
5
A
ASP
28
-154.43
24.09
5
A
PRO
44
-69.39
90.27
5
A
PHE
47
-62.83
-149.45
5
A
PRO
53
-65.47
97.43
6
A
MET
3
-171.27
-78.97
6
A
ASP
4
-47.99
88.85
6
A
GLU
7
-19.72
82.85
6
A
PHE
8
-160.85
-151.62
6
A
LEU
11
-52.31
176.22
6
A
CYS
12
-19.47
62.60
6
A
ARG
13
-86.00
34.99
6
A
LYS
16
-19.31
61.69
6
A
MET
17
-61.37
55.55
6
A
LEU
18
-171.15
58.32
6
A
ASP
20
-49.77
-178.53
6
A
ASP
28
-164.85
28.57
6
A
PHE
47
-60.97
-118.42
7
A
HIS
2
-106.25
57.60
7
A
ASP
4
179.67
61.72
7
A
GLU
7
-18.80
80.68
7
A
PHE
8
-160.35
-144.54
7
A
LEU
11
-66.82
-178.58
7
A
CYS
12
-18.30
60.41
7
A
LYS
16
-19.79
58.71
7
A
MET
17
-61.94
74.14
7
A
LEU
18
-171.11
59.75
7
A
ASP
20
-63.91
-177.10
7
A
ASP
28
-154.83
23.89
7
A
ARG
34
-111.39
-71.13
7
A
PRO
44
-57.55
71.19
7
A
CYS
54
-157.01
-44.91
8
A
HIS
2
-129.06
-151.83
8
A
MET
3
-68.47
-161.47
8
A
ASP
4
-34.20
93.78
8
A
GLU
7
-25.53
86.14
8
A
PHE
8
-160.66
-157.30
8
A
CYS
12
-19.82
59.58
8
A
ARG
13
-81.47
32.47
8
A
LYS
16
-19.41
60.54
8
A
MET
17
-49.13
66.67
8
A
LEU
18
-171.19
52.31
8
A
ILE
26
-159.96
88.65
8
A
ASP
28
-146.94
21.05
8
A
PHE
47
-51.52
175.16
8
A
CYS
54
-167.70
-41.73
9
A
HIS
2
-140.93
-152.18
9
A
MET
3
-67.12
71.69
9
A
CYS
5
-133.98
-140.19
9
A
GLU
7
-19.17
75.59
9
A
PHE
8
-160.71
-153.23
9
A
CYS
12
-18.78
67.03
9
A
ARG
13
-94.04
38.30
9
A
LYS
16
-19.28
61.54
9
A
MET
17
-62.80
54.36
9
A
LEU
18
-170.88
65.80
9
A
ASP
20
-49.36
179.98
9
A
ASP
28
-154.15
24.90
9
A
PRO
44
-58.85
78.99
9
A
PHE
47
-52.48
-175.55
10
A
HIS
2
-69.62
65.68
10
A
MET
3
-117.70
-88.98
10
A
ASP
4
-42.22
164.36
10
A
CYS
5
-161.07
-167.65
10
A
THR
6
-44.16
-88.06
10
A
GLU
7
178.83
-28.03
10
A
PHE
8
-152.08
-152.03
10
A
LEU
11
-48.63
-163.15
10
A
CYS
12
-16.78
69.73
10
A
ARG
13
-97.44
31.40
10
A
ASN
15
-170.18
-52.00
10
A
LYS
16
-19.53
56.85
10
A
MET
17
-67.59
77.20
10
A
LEU
18
-170.67
59.77
10
A
ASP
20
-57.41
176.71
10
A
LEU
21
-156.29
84.52
10
A
ASP
28
-158.53
26.73
10
A
PHE
47
-48.76
161.33
10
A
CYS
54
-130.10
-52.75
11
A
HIS
2
-124.30
-154.29
11
A
MET
3
-67.11
-166.75
11
A
CYS
5
-79.98
-134.61
11
A
THR
6
-64.15
-72.03
11
A
GLU
7
179.26
-19.89
11
A
PHE
8
-156.10
-156.88
11
A
PRO
10
-64.71
83.25
11
A
LEU
11
-43.85
-167.51
11
A
CYS
12
-17.26
64.27
11
A
ASN
15
-170.54
-70.14
11
A
LYS
16
-70.28
34.12
11
A
MET
17
-43.64
151.80
11
A
LEU
18
-69.60
62.68
11
A
ASP
28
-157.01
25.04
11
A
CYS
54
174.99
-36.87
12
A
HIS
2
-95.42
32.38
12
A
MET
3
-159.98
-110.04
12
A
GLU
7
-19.97
81.12
12
A
PHE
8
-160.75
-152.22
12
A
LEU
11
-52.54
174.46
12
A
CYS
12
-19.36
64.06
12
A
ARG
13
-92.58
42.20
12
A
LYS
16
-61.27
52.28
12
A
MET
17
-34.12
119.68
12
A
ASP
28
-155.86
22.73
12
A
PRO
44
-50.72
-177.27
12
A
PHE
47
-38.18
-111.10
12
A
CYS
54
-169.84
-77.33
13
A
ASP
4
-159.52
77.62
13
A
THR
6
-60.87
-119.47
13
A
GLU
7
179.05
26.24
13
A
LEU
11
-54.01
-169.30
13
A
CYS
12
-17.69
66.35
13
A
ARG
13
-100.03
42.99
13
A
LYS
16
-22.67
60.73
13
A
MET
17
-64.65
65.47
13
A
LEU
18
-171.35
107.78
13
A
ASP
20
-59.20
175.85
13
A
ASP
28
-159.73
32.55
13
A
PRO
44
-66.42
84.41
13
A
PHE
47
-54.13
-176.27
13
A
CYS
54
-115.18
-90.81
14
A
MET
3
-172.98
-54.43
14
A
ASP
4
-47.46
106.38
14
A
CYS
5
-160.27
-162.19
14
A
GLU
7
-19.26
84.43
14
A
PHE
8
-160.46
-160.71
14
A
LEU
11
-55.61
175.20
14
A
CYS
12
-19.80
67.62
14
A
ARG
13
-86.60
40.67
14
A
CYS
14
-129.36
-167.71
14
A
ASN
15
-110.25
-146.58
14
A
MET
17
-52.45
-171.46
14
A
LEU
18
-68.89
68.74
14
A
ASP
28
-151.30
23.50
14
A
ARG
34
-81.70
-76.58
14
A
CYS
54
-178.43
-63.97
15
A
ASP
4
179.90
72.87
15
A
THR
6
-59.65
-107.75
15
A
GLU
7
179.47
23.31
15
A
PRO
10
-64.59
76.88
15
A
LEU
11
-50.85
-169.15
15
A
CYS
12
-17.78
65.32
15
A
ARG
13
-86.33
36.15
15
A
LYS
16
-37.21
59.89
15
A
MET
17
-53.18
81.19
15
A
LEU
18
-170.89
51.86
15
A
ASP
20
-51.73
-177.12
15
A
ASP
28
-155.26
25.57
15
A
PRO
44
-72.78
49.95
15
A
PHE
47
-63.53
-124.10
15
A
GLU
48
-160.35
116.44
15
A
CYS
54
-129.18
-56.70
16
A
MET
3
-170.00
-92.18
16
A
ASP
4
-43.77
106.52
16
A
GLU
7
-40.88
81.21
16
A
PHE
8
-160.60
-150.55
16
A
LEU
11
-59.62
171.94
16
A
CYS
12
-19.41
63.42
16
A
LYS
16
-18.70
58.20
16
A
MET
17
-64.46
82.62
16
A
ASP
28
-164.45
28.24
16
A
ARG
34
-96.58
-61.81
16
A
PRO
44
-56.27
84.77
16
A
PHE
47
-19.68
-107.33
16
A
CYS
54
-153.17
-34.28
17
A
MET
3
-136.33
-137.83
17
A
ASP
4
-29.54
80.57
17
A
CYS
5
-161.53
-162.91
17
A
GLU
7
-86.30
49.55
17
A
PHE
8
-160.20
-151.32
17
A
CYS
12
-17.78
62.39
17
A
CYS
14
-170.38
108.54
17
A
ASN
15
-73.35
-96.06
17
A
MET
17
-52.09
176.68
17
A
LEU
18
-69.07
71.54
17
A
ASP
28
-154.52
24.04
17
A
ARG
34
-98.20
-66.95
17
A
PHE
47
-61.67
-119.14
17
A
CYS
54
-161.57
-67.30
18
A
MET
3
-171.07
118.77
18
A
ASP
4
-155.95
51.88
18
A
GLU
7
177.99
-17.90
18
A
PHE
8
-156.20
-148.89
18
A
PRO
10
-60.17
78.25
18
A
LEU
11
-52.80
-162.82
18
A
CYS
12
-17.14
66.92
18
A
LYS
16
-19.35
58.86
18
A
MET
17
-65.15
66.17
18
A
LEU
18
-170.38
52.40
18
A
ASP
20
-62.68
-179.63
18
A
ASP
28
-150.25
20.48
18
A
PRO
44
-54.11
85.91
18
A
PHE
47
-29.19
-110.69
18
A
SER
50
-151.94
79.90
18
A
CYS
54
-176.63
-68.27
19
A
HIS
2
-130.64
-153.12
19
A
MET
3
-68.70
-159.18
19
A
ASP
4
-19.63
130.74
19
A
THR
6
-35.49
-30.52
19
A
GLU
7
-18.58
85.01
19
A
PHE
8
-160.32
-141.61
19
A
ASN
9
-69.34
-74.56
19
A
LEU
11
-40.35
169.05
19
A
CYS
12
-18.81
60.41
19
A
ARG
13
-91.95
39.66
19
A
LYS
16
-19.40
58.49
19
A
LEU
18
-170.44
65.88
19
A
ASP
20
-53.63
178.62
19
A
ASP
28
-152.08
23.97
19
A
PHE
47
-50.96
174.73
19
A
CYS
54
-151.80
-47.58
20
A
MET
3
-170.51
-36.88
20
A
CYS
5
-150.34
-139.44
20
A
THR
6
-66.10
-70.57
20
A
GLU
7
179.64
-28.87
20
A
PHE
8
-161.04
-141.26
20
A
PRO
10
-66.66
72.39
20
A
LEU
11
-46.27
-158.27
20
A
CYS
12
-17.33
65.73
20
A
ARG
13
-93.77
32.07
20
A
LYS
16
-19.49
61.49
20
A
MET
17
-45.48
63.88
20
A
LEU
18
-171.19
57.50
20
A
ASP
28
-153.84
22.17
20
A
PRO
44
-53.11
86.93
20
A
PHE
47
-56.55
-114.67
20
A
SER
50
-155.62
82.30
20
A
CYS
54
-133.44
-68.19
Solution structure of ascidian trypsin inhibitor
1
N
N
A
ASN
35
A
ASN
35
HELX_P
A
HIS
43
A
HIS
43
1
1
9
disulf
2.028
A
CYS
5
A
SG
CYS
5
1_555
A
CYS
40
A
SG
CYS
40
1_555
disulf
2.024
A
CYS
12
A
SG
CYS
12
1_555
A
CYS
41
A
SG
CYS
41
1_555
disulf
2.032
A
CYS
14
A
SG
CYS
14
1_555
A
CYS
37
A
SG
CYS
37
1_555
disulf
2.030
A
CYS
23
A
SG
CYS
23
1_555
A
CYS
54
A
SG
CYS
54
1_555
PROTEIN BINDING
solution structure, ascidian, trypsin inhibitor, cystine-stabilized alpha-helical motif, disulfide bond, Kazal-type inhibitor, PROTEIN BINDING
ITRP_HALRO
UNP
1
1
P16589
AHMDCTEFNPLCRCNKMLGDLICAVIGDAKEEHRNMCALCCEHPGGFEYSNGPCE
1
55
1IW4
1
55
P16589
A
1
1
55
3
anti-parallel
anti-parallel
A
GLU
31
A
GLU
31
A
HIS
33
A
HIS
33
A
ILE
22
A
ILE
22
A
VAL
25
A
VAL
25
A
GLU
48
A
GLU
48
A
TYR
49
A
TYR
49